Related Articles
Blood‑based microRNAs as diagnostic biomarkers to discriminate localized prostate cancer from benign prostatic hyperplasia and allow cancer‑risk stratification
Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone
Progression of prostate cancer: Diagnostic and prognostic utility of prostate-specific antigen, α2-macroglobulin, and their complexes
Serum thymidine kinase 1 is associated with Gleason score of patients with prostate carcinoma
Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia